濮阳东方医院妇科价格不高(濮阳东方妇科医院收费低服务好) (今日更新中)

The Secret Service arrested a man near the White House on Monday, after they had been told to be on the lookout for a man who allegedly threatened to kill "all white police" there.Monday afternoon, police in Montgomery County, Maryland, alerted the US Secret Service that the man planned to go to Washington with the purpose of killing officers at the White House, according to a USSS statement. About an hour later, Secret Service officers spotted him on Pennsylvania Avenue near Lafayette Park, according to the statement. He was arrested without incident. Officials say charges are pending.The Secret Service's protective intelligence division was notified at about 2:55 p.m. ET to be on the lookout for Michael Arega of Dallas, who the Montgomery County Maryland Police Department said was heading to Washington for the purpose of killing "all white police" at the White House, according to the statement. The Secret Service spotted him at approximately 4:05 p.m. ET.He was "immediately detained by Secret Service Uniformed Division Officers and subsequently arrested without incident," according to the statement. 1126

The star of the Netflix documentary "Tiger King" Joe Exotic sued the United States Justice Department Wednesday because they rejected his request for a presidential pardon.According to court documents obtained by CBS11 and Courthouse News, lawyers for Exotic, whose real name Joseph Maldonado-Passage, argued that the rejection isn't valid because Acting Pardon Attorney Rosalind Sargent-Burns didn't give his official request to President Donald Trump himself.According to the six-page complaint filed in federal court in Fort Worth, Exotic's legal team named Sargent-Burns because she allegedly never gave President Trump a formal recommendation, which according to the lawsuit, she's required to do.Currently, Maldonado-Passage is serving a 22-year prison sentence in Fort Worth after he was found guilty in April 2019 for animal cruelty and trying to hire someone to murder Carole Baskin, who's a big-cat rights activist.The complaint also names Donald Trump Jr. as a supporter, CBS11 reported. 1006

The Stallion Springs, California Police Department is warning the public about a cell phone "spoofing" scam that's going around asking for personal information. The spoofing scam appears to look like a legitimate phone call as the caller ID is displayed as the victim's own cellphone number.A voice recording identifies the call is coming from AT&T, and advises the victim that their cellphone account has been compromised and they may be a victim of fraud. The voice recording then asks for the victim to confirm their personal information, specifically asking for the last four digits of their social security number.AT&T confirmed to Stallion Springs Police that this is a phone scam. Police advise that if you receive calls like this, to not answer them. If you do answer, do not give out your personal information. Hang up and call your phone company asking about the legitimacy of the scam or call police. Report spoofing at www.IC3.gov. 989

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Senate is expected to vote on an economic relief package this week and while it has little chance of passing the House, it is sending a very clear message to airlines: help may not be coming. United Airlines and American Airlines have both threatened thousands of their employees with layoffs if government assistance doesn't come before October 1. October 1 is the first date airlines that took bailout money from earlier this year can layoff workers under the terms set by Congress. United is looking at cutting around 16,000 employees while American is slashing around 19,000 workers. Southwest and Delta, notably, are not laying off workers after offering buyouts to many workers. For weeks, airlines and unions were holding out hope lawmakers would pass a bill after returning from their August recess. The Association of Flight Attendants took to Capitol Hill Wednesday to demand action. 906

来源：资阳报